Chennai Meenakshi Multispeciality Hospital Ltd vs Indraprastha Medical Corporation Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Nov 01, 2026

Key Highlights

The Latest Trading Price of Chennai Meenakshi Multispeciality Hospital Ltd is ₹ 33.15 as of 30 Oct 15:30 . The P/E Ratio of Chennai Meenakshi Multispeciality Hospital Ltd changed from 4.3 on March 2022 to 0 on March 2026 . This represents a CAGR of -100.00% over 5 yearsThe P/E Ratio of Indraprastha Medical Corporation Ltd changed from 215 on March 2021 to 18.5 on March 2026 . This represents a CAGR of -33.56% over 6 years The Market Cap of Chennai Meenakshi Multispeciality Hospital Ltd changed from ₹ 7.28 crore on March 2021 to ₹ 24.66 crore on March 2026 . This represents a CAGR of 22.55% over 6 yearsThe Market Cap of Indraprastha Medical Corporation Ltd changed from ₹ 492.74 crore on March 2021 to ₹ 3407 crore on March 2026 . This represents a CAGR of 38.03% over 6 years The revenue of Chennai Meenakshi Multispeciality Hospital Ltd for the Sep '26 is ₹ 0 crore as compare to the Jun '26 revenue of ₹ 8.7 crore. This represent the decline of -100% The revenue of Indraprastha Medical Corporation Ltd for the Sep '26 is ₹ 421.4 crore as compare to the Jun '26 revenue of ₹ 414.57 crore. This represent the growth of 1.65% The ebitda of Chennai Meenakshi Multispeciality Hospital Ltd for the Sep '26 is ₹ 0 crore as compare to the Jun '26 ebitda of ₹ 0.46 crore. This represent the decline of -100% The ebitda of Indraprastha Medical Corporation Ltd for the Sep '26 is ₹ 85.99 crore as compare to the Jun '26 ebitda of ₹ 88.23 crore. This represent the decline of -2.54% The net profit of Chennai Meenakshi Multispeciality Hospital Ltd changed from ₹ -0.38 crore to ₹ 0 crore over 10 quarters. This represents a CAGR of -100.00% The net profit of Indraprastha Medical Corporation Ltd changed from ₹ 44.77 crore to ₹ 53.58 crore over 10 quarters. This represents a CAGR of 7.45% The Dividend Payout of Chennai Meenakshi Multispeciality Hospital Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 yearsThe Dividend Payout of Indraprastha Medical Corporation Ltd changed from 39.1 % on March 2022 to 19.97 % on March 2026 . This represents a CAGR of -12.57% over 5 years .

About Chennai Meenakshi Multispeciality Hospital Ltd

Chennai Meenakshi Multispeciality Hospital Limited, formerly known as Devaki Hospital Limited, was incorporated in 1990.
The Company name was changed from Devaki Hospital Limited to Chennai Meenakshi Multispeciality Hospital Limited in October, 2007.
It is a 100-bedded hospital located in the heart of Chennai at Mylapore.
The hospital has an infrastructure comprising of around 105 Beds including ICU Beds, Operating Theatre, a modern dialysis Unit besides a host of other facilities.
The Company has a pool of talented and experienced doctors who are further supported by a team of highly qualified and experienced and dedicated support staff and cutting edge technology. The Company operate into various departments like Cardiology Department; Casualty Department; Diagnostic Services; Intensive Care Unit; Nephrology Department and Physiotherapy Department.

About Indraprastha Medical Corporation Ltd

Indraprastha Medical Corporation Limited was incorporated on 16th March, 1988.
The main business of the Company is to enhance the quality of life of patients by providing comprehensive, high-quality hospital services on a cost-effective basis.
The Company was formed as a joint venture between the Government of Delhi and the Apollo Hospitals Group to establish the Indraprastha Apollo Hospitals. The Hospital provides international standard medical care, offering a wide range of multi-specialty services.
Key specialties with strong growth and revenue potential include transplants, cardiology, oncology, neurology, and orthopaedics. The company came out with the public issue of 2,29,18,300 equity shares of Rs 10 each for cash at par aggregating Rs 22,91,83,000.
IMCL is setting up a multi-disciplinary super speciality teritary care referral hospital at New Delhi.

FAQs for the comparison of Chennai Meenakshi Multispeciality Hospital Ltd and Indraprastha Medical Corporation Ltd

Which company has a larger market capitalization, Chennai Meenakshi Multispeciality Hospital Ltd or Indraprastha Medical Corporation Ltd?

Market cap of Chennai Meenakshi Multispeciality Hospital Ltd is 24 Cr while Market cap of Indraprastha Medical Corporation Ltd is 2,797 Cr

What are the key factors driving the stock performance of Chennai Meenakshi Multispeciality Hospital Ltd and Indraprastha Medical Corporation Ltd?

The stock performance of Chennai Meenakshi Multispeciality Hospital Ltd and Indraprastha Medical Corporation Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Chennai Meenakshi Multispeciality Hospital Ltd and Indraprastha Medical Corporation Ltd?

As of November 1, 2026, the Chennai Meenakshi Multispeciality Hospital Ltd stock price is INR ₹33.15. On the other hand, Indraprastha Medical Corporation Ltd stock price is INR ₹305.15.

How do dividend payouts of Chennai Meenakshi Multispeciality Hospital Ltd and Indraprastha Medical Corporation Ltd compare?

To compare the dividend payouts of Chennai Meenakshi Multispeciality Hospital Ltd and Indraprastha Medical Corporation Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.